Menu +

Publications

Excess cortisol and its adverse effects are the focus of Corcept’s research and our collaborations with investigators around the world. Because excess cortisol affects virtually every organ in the body, this research and the resulting publications address a variety of pre-clinical models and potential indications.

Glucocorticoid receptor antagonism as a novel therapy for triple-negative breast cancer. Clin Cancer Res. 2013 Sep 9. [Epub ahead of print] Skor MN, Wonder EL, Kocherginsky M, Goyal A, Hall BA, Cai Y, Conzen SD. View the PubMed Abstract

Glucocorticoid receptor antagonism as a novel therapy for triple-negative breast cancer. Clin Cancer Res. 2013 Nov 15 ;19(22):6163-72. doi: 10.1158/1078-0432.CCR-12-3826. Epub 2013 Sep 9 . Skor MN, Wonder EL, Kocherginsky M, Goyal A, Hall BA, Cai Y, Conzen SD. View the PubMed Abstract

Nuclear Receptors and Breast Cancer. Molecular Endocrinology. 2008 22(10):2215–2228. doi: 10.1210/me.2007-0421 Conzen Suzanne D. View the PubMed Abstract

Steroid Receptors Aplenty in Prostate Cancer. N Engl J Med. 2014 370 (10) 970-971. doi: 10.1056/NEJMcibr1315706. Sharifi Nima. View the PubMed Abstract

Mifepristone alters amyloid precursor protein processing to preclude amyloid beta and also reduces tau pathology. Biol Psychiatry. 2013 Sep 1;74(5):357-66. doi: 10.1016/j.biopsych.2012.12.003. Epub 2013 Jan 8. Baglietto-Vargas D, Medeiros R, Martinez-Coria H, LaFerla FM, Green KN. View the PubMed Abstract

A Pilot Study of Mifepristone in Combat-Related PTSD. Depress Res Treat. 2012;2012:393251. doi: 10.1155/2012/393251. Epub 2012 Apr 24. Golier JA, Caramanica K, Demaria R, Yehuda R. View the PubMed Abstract

Mifepristone treatment of olanzapine-induced weight gain in healthy men. Adv Ther. 2009 Oct;26(10):959-69. doi: 10.1007/s12325-009-0070-1. Epub 2009 Nov 4. Gross C, Blasey CM, Roe RL, Allen K, Block TS, Belanoff JK. View the PubMed Abstract

Mifepristone reduces weight gain and improves metabolic abnormalities associated with risperidone treatment in normal men. Obesity (Silver Spring). 2010 Dec;18(12):2295-300. doi: 10.1038/oby.2010.51. Epub 2010 Mar 25. Gross C, Blasey CM, Roe RL, Belanoff JK. View the PubMed Abstract

Corticosteroid-dependent plasticity mediates compulsive alcohol drinking in rats. J Neurosci. 2012 May 30;32(22):7563-71. doi: 10.1523/JNEUROSCI.0069-12.2012. Vendruscolo LF, Barbier E, Schlosburg JE, Misra KK, Whitfield TW Jr, Logrip ML, Rivier C, Repunte-Canonigo V, Zorrilla EP, Sanna PP, Heilig M, Koob GF. View the PubMed Abstract

Serum/glucocorticoid-regulated kinase 1 expression in primary human prostate cancers. Prostate. 2012 Feb 1 ;72(2):157-64. doi: 10.1002/pros.21416. Epub 2011 May 11 Szmulewitz RZ, Chung E, Al-Ahmadie H, Daniel S, Kocherginsky M, Razmaria A, Zagaja GP, Brendler CB, Stadler WM, Conzen S. View the PubMed Abstract

Glucocorticoid receptor activity contributes to resistance to androgen-targeted therapy in prostate cancer. Horm Cancer. 2014 Apr ;5(2):72-89. doi: 10.1007/s12672-014-0173-2. Epub 2014 Mar 11 . Isikbay M, Otto K, Kregel S, Kach J, Cai Y, Vander Griend DJ, Conzen SD, Szmulewitz RZ. View the PubMed Abstract

"Targeting" triple-negative breast cancer: the lessons learned from BRCA1-associated breast cancers. Semin Oncol. 2011 Apr ;38(2):254-62. doi: 10.1053/j.seminoncol.2011.01.007. Nanda R. View the PubMed Abstract

The influence of glucocorticoid signaling on tumor progression. Brain Behav Immun. 2013 Mar ;30 Suppl:S26-31. doi: 10.1016/j.bbi.2012.10.022. Epub 2012 Nov 16 . Volden PA, Conzen SD. View the PubMed Abstract

Mifepristone prevents repopulation of ovarian cancer cells escaping cisplatin-paclitaxel therapy. BMC Cancer. 2012 Jun 22 ;12:200. doi: 10.1186/1471-2407-12-200. Gamarra-Luques CD, Goyeneche AA, Hapon MB, Telleria CM. View the PubMed Abstract

Mifepristone inhibits GRβ coupled prostate cancer cell proliferation. J Urol. 2012 Sep ;188(3):981-8. doi: 10.1016/j.juro.2012.04.102. Epub 2012 Jul 21 . Ligr M, Li Y, Logan SK, Taneja S, Melamed J, Lepor H, Garabedian MJ, Lee P. View the PubMed Abstract

Re: mifepristone inhibits GRβ coupled prostate cancer cell proliferation. J Urol. 2013 May ;189(5):1993-4. doi: 10.1016/j.juro.2012.11.116. Epub 2012 Nov 28 . Kapoor S. View the PubMed Abstract

Mifepristone treatment of chronic central serous chorioretinopathy. Retina. 2007 Jan ;27(1):119-22. Nielsen JS, Weinreb RN, Yannuzzi L, Jampol LM. View the PubMed Abstract

A single-day treatment with mifepristone is sufficient to normalize chronic glucocorticoid induced suppression of hippocampal cell proliferation. PLoS One. 2012;7(9):e46224. doi: 10.1371/journal.pone.0046224. Epub 2012 Sep 25. Hu P, Oomen C, van Dam AM, Wester J, Zhou JN, Joëls M, Lucassen PJ. View the PubMed Abstract

Acute effects of neonatal dexamethasone treatment on proliferation and astrocyte immunoreactivity in hippocampus and corpus callosum: towards a rescue strategy. Brain Res. 2012 Oct 30;1482:1-12. doi: 10.1016/j.brainres.2012.08.017. Epub 2012 Aug 16. Claessens SE, Belanoff JK, Kanatsou S, Lucassen PJ, Champagne DL, de Kloet ER. View the PubMed Abstract

Publications related to Corcept’s proprietary molecules

Administration of a selective glucocorticoid antagonist attenuates electroconvulsive shock-induced retrograde amnesia. J Neural Transm. 2012 Mar;119(3):337-44. doi: 10.1007/s00702-011-0712-8. Epub 2011 Sep 16. Andrade C, Shaikh SA, Narayan L, Blasey C, Belanoff J. View the PubMed Abstract

Differential targeting of brain stress circuits with a selective glucocorticoid receptor modulator. Proc Natl Acad Sci U S A. 2013 May 7;110(19):7910-5. doi: 10.1073/pnas.1219411110. Epub 2013 Apr 23. Zalachoras I, Houtman R, Atucha E, Devos R, Tijssen AM, Hu P, Lockey PM, Datson NA, Belanoff JK, Lucassen PJ, Joëls M, de Kloet ER, Roozendaal B, Hunt H, Meijer OC. View the PubMed Abstract

Selective glucocorticoid receptor (type II) antagonists prevent weight gain caused by olanzapine in rats. Eur J Pharmacol. 2011 Mar 25;655(1-3):117-20. doi: 10.1016/j.ejphar.2011.01.019. Epub 2011 Jan 24. Belanoff JK, Blasey CM, Clark RD, Roe RL. View the PubMed Abstract

Selective Glucocorticoid Receptor (GR) Antagonist Reduces Body Weight Gain in Mice. J Nutr Metab. 2011;2011:235389. doi: 10.1155/2011/235389. Epub 2011 Jul 28. Asagami T, Belanoff JK, Azuma J, Blasey CM, Clark RD, Tsao PS. View the PubMed Abstract

The selective glucocorticoid receptor modulator CORT108297 restores faulty hippocampal parameters in Wobbler and corticosterone-treated mice. J Steroid Biochem Mol Biol. 2014 Feb 22;143C:40-48. doi: 10.1016/j.jsbmb.2014.02.007. [Epub ahead of print] Meyer M, Gonzalez Deniselle MC, Hunt H, Kloet ER, De Nicola AF. View the PubMed Abstract

2-Benzenesulfonyl-8a-benzyl-hexahydro-2H-isoquinolin-6-ones as selective glucocorticoid receptor antagonists. Bioorg Med Chem Lett. 2007 Oct 15;17(20):5704-8. Epub 2007 Aug 19. Clark RD, Ray NC, Blaney P, Crackett PH, Hurley C, Williams K, Dyke HJ, Clark DE, Lockey PM, Devos R, Wong M, White A, Belanoff JK. View the PubMed Abstract

1H-Pyrazolo[3,4-g]hexahydro-isoquinolines as selective glucocorticoid receptor antagonists with high functional activity. Bioorg Med Chem Lett. 2008 Feb 15;18(4):1312-7. doi: 10.1016/j.bmcl.2008.01.027. Epub 2008 Jan 11. Clark RD, Ray NC, Williams K, Blaney P, Ward S, Crackett PH, Hurley C, Dyke HJ, Clark DE, Lockey P, Devos R, Wong M, Porres SS, Bright CP, Jenkins RE, Belanoff J. View the PubMed Abstract

Discovery and optimization of novel, non-steroidal glucocorticoid receptor modulators. Bioorg Med Chem Lett. 2007 Sep 1;17(17):4901-5. Epub 2007 Jun 13. Ray NC, Clark RD, Clark DE, Williams K, Hickin HG, Crackett PH, Dyke HJ, Lockey PM, Wong M, Devos R, White A, Belanoff JK. View the PubMed Abstract

Discovery of a novel non-steroidal GR antagonist with in vivo efficacy in the olanzapine-induced weight gain model in the rat. Bioorg Med Chem Lett. 2012 Dec 15;22(24):7376-80. doi: 10.1016/j.bmcl.2012.10.074. Epub 2012 Oct 23. Hunt HJ, Ray NC, Hynd G, Sutton J, Sajad M, O'Connor E, Ahmed S, Lockey P, Daly S, Buckley G, Clark RD, Roe R, Blasey C, Belanoff J. View the PubMed Abstract

built@zoomedia
You are now leaving this website. If you would like to continue, click Continue.
Cancel Continue